Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Biotech
Boehringer spells out a $448M future for Rectify's ABC program
Boehringer has opened another front in its attack on chronic kidney disease, offering Rectify up to $448 million to partner on a preclinical program.
Nick Paul Taylor
Dec 22, 2025 9:45am
Novo vs. KBP Chapter 4: Lessons from the $1.3B fallout
Oct 2, 2025 3:00am
ProKidney cell therapy wins half of trial, falls short on other
Jul 8, 2025 8:00am
Mineralys drug lowers blood pressure in yet another clinical win
Jun 17, 2025 9:25am
Otsuka's kidney disease drug halves UPCR levels in ph. 3 study
Jun 6, 2025 6:26am
Former Pfizer antibody reduces cardio risk marker in ph. 2
May 20, 2025 7:30am
